Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Ian Mills

University of Oxford

United Kingdom

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Cell Biology

100%

Biostatistics

60%

Cancer Biology

100%

Prostate Cancer

50%

Cell Signaling

40%

Radiogenomics

30%

Tumor Progression

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles23

A Novel Primary Cell Line Model of Localized Prostate Cancer and Radioresistance—A Role for Nicotinamide N-Methyltransferase

Article Link

Year:

2025

Clonal phylogenies inferred from bulk, single cell, and spatial transcriptomic analysis of epithelial cancers

Article Link

Year:

2025

CDK9 inhibition activates innate immune response through viral mimicry

Article Link

Year:

2024

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post‐radiotherapy, and those with de novo metastatic disease

Article Link

Year:

2024

Adaptations of membrane trafficking in cancer and tumorigenesis

Article Link

Year:

2024

Identifying proteomic risk factors for cancer using prospective and exome analyses of 1463 circulating proteins and risk of 19 cancers in the UK Biobank

Article Link

Year:

2024

Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with histopathological features

Article Link

Year:

2024

Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer

Article Link

Year:

2024

Metabolic imaging across scales reveals distinct prostate cancer phenotypes

Article Link

Year:

2024

Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy

Article Link

Year:

2024

Identifying proteomic risk factors for overall, aggressive, and early onset prostate cancer using Mendelian Randomisation and tumour spatial transcriptomics

Article Link

Year:

2024

Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types

Article Link

Year:

2023

The role of CaMKK2 in Golgi-associated vesicle trafficking

Article Link

Year:

2023

Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence

Article Link

Year:

2023

Molecular Anatomy of Prostate Cancer and Its Implications in Active Surveillance and Early Intervention Strategies

Article Link

Year:

2023

VPRBP Functions Downstream of the Androgen Receptor and OGT to Restrict p53 Activation in Prostate Cancer

Article Link

Year:

2022

Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist–Treated Prostate Cancers

Article Link

Year:

2022

CaMKK2 facilitates Golgi-associated vesicle trafficking to sustain cancer cell proliferation

Article Link

Year:

2021

Vascular normalisation as the stepping stone into tumour microenvironment transformation

Article Link

Year:

2021

Transcript analysis of commercial prostate cancer risk stratification panels in hard‐to‐predict grade group 2–4 prostate cancers

Article Link

Year:

2021

O-GlcNAc Transferase – An Auxiliary Factor or a Full-blown Oncogene?

Article Link

Year:

2021

Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.

Article Link

Year:

2021

Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells.

Article Link

Year:

2021

Collaborators23

Thomas Kislinger

Professor

University of Toronto

CANADA

Tapio Visakorpi

FINLAND

Nora Pashayan

Professor of Applied Cancer Research

University College London

UNITED KINGDOM

Kirsi Johanna Rautajoki

Tampere University

FINLAND

Minh-Phuong Huynh-Le

George Washington University

UNITED STATES

Tyler Seibert

Assistant Professor

University of California, San Diego

UNITED STATES

Aliisa Tiihonen

University of Tampere

FINLAND

Timo-Pekka K. Lehto

University of Helsinki

FINLAND

Daniel Longley

The Queen's University Belfast

UNITED KINGDOM

Francisco Guerra Liberal

The Queen's University Belfast

UNITED KINGDOM

Trishna Desai

University of Oxford

UNITED KINGDOM

Yong-Jie Lu

Professor in Molecular Oncology

Queen Mary University of London

UNITED KINGDOM

Matti Nykter

Professor

University of Tampere

FINLAND

Sarah Maguire

Lecturer in Applied Genmoics and Bioinformatics

The Queen's University Belfast

UNITED KINGDOM

Tristan Barrett

UNITED KINGDOM

Richard Bryant

University of Oxford

UNITED KINGDOM

Freddie Hamdy

Head of Department

University of Oxford

UNITED KINGDOM

Roni Haas

David Geffen School of Medicine at UCLA

UNITED STATES

David Wedge

The University of Manchester

UNITED KINGDOM

Emma Evergren

The Queen's University Belfast

UNITED KINGDOM

Harri Itkonen

University of Helsinki

FINLAND

DAVID WAUGH

Head of School, Professor of Molecular Oncology & Therapeutics

Queensland University of Technology

AUSTRALIA

Simon McDade

The Queen's University Belfast

UNITED KINGDOM

How do I reach out?

Meet Kite AI